E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
non-small cell lung cancer |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029521 |
E.1.2 | Term | Non-small cell lung cancer stage IIIB |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029522 |
E.1.2 | Term | Non-small cell lung cancer stage IV |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the pharmacokinetics of docetaxel and cisplatin in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated with pravastatin, docetaxel and cisplatin, and to estimate the PK interaction between pravastatin, docetaxel and cisplatin. |
|
E.2.2 | Secondary objectives of the trial |
To establish the safety and tolerability of pravastatin when co-administered with docetaxel and cisplatin in patients with advanced or metastatin nsclc. To make a preliminary assessment of the efficacy of docetaxel and cisplatin when co-administered with pravastatin in patients with advanced or metastatic nsclc. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Stage IIIB disease that is unsuitable to radio-chemotherapy or Stage IV disease. •Estimated life expectancy of at least 12 weeks. •ECOG Performance status 0, 1 or 2 •Aged 18 or over. •Patient able to give informed consent •Adequate haematologic function (ANC greater than 1.5x109/L, platelets greater than 100x109/L, and haemoglobin greated than 9 g/dl). •Adequate renal function: EDTA-based or calculated (using the Wright formula; see appendix 3 or the Cockcroft-Gault formula) glomelular filtration rate of > 55 mL/min •Adequate hepato-biliary function: Serum bilirubin < 1.5xULN, AST/ALT <3xULN •Patient compliance and geographic proximity allowing for adequate follow-up. •Written informed consent prior to admission to this study
|
|
E.4 | Principal exclusion criteria |
•Symptomatic Central Nervous System (CNS) involvement. •Prior treatment with more than one chemotherapy regimen •Patient has received a statin within 2 weeks prior to registration •Creatine Kinase > 5xULN •Concomitant use of -CYP3A4 inhibitors such as cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, nefazodone, or large quantities of grapefruit juice (>250 mL/d) - Lipid-lowering drugs that can cause myopathy such as gemfibrozil, other fibrates, or lipid-lowering doses (>1 g/day) of niacin •Hypersensitivity to docetaxel, cisplatin or pravastatin or any of their excipients. •Evidence of significant medical condition or laboratory finding which, in the opinion of the investigator, makes it undesirable for the patient to participate in the trial •Evidence of uncontrolled infection. •Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study. •Pregnancy and lactation. Effective contraception (IUD, birth control pills or barrier device) is mandatory for all patients of reproductive potential if sexually active whilst in the study. Contraception should continue for 1 year post completion of all chemotherapy/radiotherapy and a further 28 days after cessation of pravastatin
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Assess the pharmacokinetics of docetaxel and cisplatin in patients with advanced or metastatic nsclc treated with pravastatin, docetaxel and cisplatin, and to estimate the PK interaction between pravastatin, docetaxel and cisplatin. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 0 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The ‘active’ phase of the trial will end 4 weeks after the last patient has finished study treatment. Subsequently, the ‘follow up’ phase of the study will then begin. All patients will be followed up until death. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |